Cytopenia and autoimmune diseases: A vicious cycle fueled by mTOR dysregulation in hematopoietic stem cells

Journal of Autoimmunity

Volumn 41, Issue , 2013, Pages 182-187

  Zheng, Pan ^a,b   Chang, Xing ^c   Lu, Qianjin ^d   Liu, Yang ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Autoimmune diseases; CD24; Cytopenia; Hematopoietic stem cells; Homeostatic proliferation; Inflammatory cytokines; MTOR; Rapamycin

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

APLASTIC ANEMIA; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CELL FUNCTION; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; GENOMIC INSTABILITY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HYPERLIPIDEMIA; IPEX SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOPENIA; MICE; MODELS, IMMUNOLOGICAL; RATS; TOR SERINE-THREONINE KINASES;

EID: 84875924628     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.12.011     Document Type: Review

References (90)

1. Goodnow C.C. Multistep pathogenesis of autoimmune disease. Cell 2007, 130:25-35.
2. Liston A., Lesage S., Wilson J., Peltonen L., Goodnow C.C. Aire regulates negative selection of organ-specific T cells. Nat Immunol 2003, 4:350-354.
3. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
4. Wang J., Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005, 25:57-62.
5. Boileau J., Mouillot G., Gerard L., Carmagnat M., Rabian C., Oksenhendler E., et al. Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. J Autoimmun 2011, 36:25-32.
6. Haymore B.R., Mikita C.P., Tsokos G.C. Common variable immune deficiency (CVID) presenting as an autoimmune disease: role of memory B cells. Autoimmun Rev 2008, 7:309-312.
7. Rensing-Ehl A., Warnatz K., Fuchs S., Schlesier M., Salzer U., Draeger R., et al. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency. Clin Immunol 2010, 137:357-365.
8. Kratz C.P., Niehues T., Lyding S., Heusch A., Janssen G., Gobel U. Evans syndrome in a patient with chromosome 22q11.2 deletion syndrome: a case report. Pediatr Hematol Oncol 2003, 20:167-172.
9. Pelkonen P., Lahdenne P., Lantto R., Honkanen V. Chronic arthritis associated with chromosome deletion 22q11.2 syndrome. J Rheumatol 2002, 29:2648-2650.
10. Davies K., Stiehm E.R., Woo P., Murray K.J. Juvenile idiopathic polyarticular arthritis and IgA deficiency in the 22q11 deletion syndrome. J Rheumatol 2001, 28:2326-2334.
11. Kawamura T., Nimura I., Hanafusa M., Fujikawa R., Okubo M., Egusa G., et al. DiGeorge syndrome with Graves' disease: a case report. Endocr J 2000, 47:91-95.
12. Sullivan K.E., McDonald-McGinn D.M., Driscoll D.A., Zmijewski C.M., Ellabban A.S., Reed L., et al. Juvenile rheumatoid arthritis-like polyarthritis in chromosome 22q11.2 deletion syndrome (DiGeorge anomalad/velocardiofacial syndrome/conotruncal anomaly face syndrome). Arthritis Rheum 1997, 40:430-436.
13. Ortega-Hernandez O.D., Agmon-Levin N., Blank M., Asherson R.A., Shoenfeld Y. The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence. J Autoimmun 2009, 32:1-6.
14. Gispen J.G., Alarcon G.S., Johnson J.J., Acton R.T., Barger B.O., Koopman W.J. Toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1987, 14:74-79.
15. Berthelot J.M., Maugars Y., Hamidou M., Chiffoleau A., Barrier J., Grolleau J.Y., et al. Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths). Rev Rhum Engl Ed 1995, 62:477-486.
16. Czaja A.J. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008, 7:319-333.
17. Rahman P., Humphrey-Murto S., Gladman D.D., Urowitz M.B. Cytotoxic therapy in systemic lupus erythematosus. Experience from a single center. Medicine (Baltimore) 1997, 76:432-437.
18. Shoda H., Inokuma S., Yajima N., Tanaka Y., Oobayashi T., Setoguchi K. Higher maximal serum concentration of methotrexate predicts the incidence of adverse reactions in Japanese rheumatoid arthritis patients. Mod Rheumatol 2007, 17:311-316.
19. Goldrath A.W., Bevan M.J. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity 1999, 11:183-190.
20. Min B., McHugh R., Sempowski G.D., Mackall C., Foucras G., Paul W.E. Neonates support lymphopenia-induced proliferation. Immunity 2003, 18:131-140.
21. Ernst B., Lee D.S., Chang J.M., Sprent J., Surh C.D. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 1999, 11:173-181.
22. Surh C.D., Sprent J. Homeostatic T cell proliferation: how far can T cells be activated to self-ligands?. J Exp Med 2000, 192:F9-F14.
23. King C., Ilic A., Koelsch K., Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004, 117:265-277.
24. Chang X., Zheng P., Liu Y. Homeostatic proliferation in mice with germline FoxP3 mutation and its contribution to fatal autoimmunity. J Immunol 2008, 181:2399-2406.
25. Kao A.H., Manzi S., Ramsey-Goldman R. Review of ACR hematologic criteria in systemic lupus erythematosus. Lupus 2004, 13:865-868.
26. Quintero O.L., Rojas-Villarraga A., Mantilla R.D., Anaya J.M. Autoimmune diseases in the intensive care unit. an update. Autoimmun Rev 2013, 12:380-395.
27. Ramos-Casals M., Cervera R., Garcia-Carrasco M., Vidal J., Trejo O., Jimenez S., et al. Cytopenia and past human parvovirus B19 infection in patients with primary Sjogren's syndrome. Semin Arthritis Rheum 2000, 29:373-378.
28. Ferraccioli G.F., Tonutti E., Casatta L., Pegoraro I., De Vita S., Sala P., et al. CD4 cytopenia and occasional expansion of CD4+CD8+lymphocytes in Sjogren's syndrome. Clin Exp Rheumatol 1996, 14:125-130.
29. Goronzy J.J., Weyand C.M. Thymic function and peripheral T-cell homeostasis in rheumatoid arthritis. Trends Immunol 2001, 22:251-255.
30. Hug A., Korporal M., Schroder I., Haas J., Glatz K., Storch-Hagenlocher B., et al. Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J Immunol 2003, 171:432-437.
31. Smith H., Chen I.M., Kubo R., Tung K.S. Neonatal thymectomy results in a repertoire enriched in T cells deleted in adult thymus. Science 1989, 245:749-752.
32. Cho B.K., Rao V.P., Ge Q., Eisen H.N., Chen J. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 2000, 192:549-556.
33. Goldrath A.W., Bogatzki L.Y., Bevan M.J. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 2000, 192:557-564.
34. Godfrey V.L., Rouse B.T., Wilkinson J.E. Transplantation of T cell-mediated, lymphoreticular disease from the scurfy (sf) mouse. Am J Pathol 1994, 145:281-286.
35. Godfrey V.L., Wilkinson J.E., Rinchik E.M., Russell L.B. Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. Proc Natl Acad Sci U S A 1991, 88:5528-5532.
36. Lyon M.F., Peters J., Glenister P.H., Ball S., Wright E. The scurfy mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott-Aldrich syndrome. Proc Natl Acad Sci U S A 1990, 87:2433-2437.
37. Baud O., Goulet O., Canioni D., Le Deist F., Radford I., Rieu D., et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001, 344:1758-1762.
38. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
39. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001, 27:18-20.
40. Chatila T.A., Blaeser F., Ho N., Lederman H.M., Voulgaropoulos C., Helms C., et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000, 106:R75-R81.
41. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
42. Chang X., Gao J.X., Jiang Q., Wen J., Seifers N., Su L., et al. The scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J Exp Med 2005, 202:1141-1151.
43. Li O., Zheng P., Liu Y. CD24 expression on T cells is required for optimal T cell proliferation in lymphopenic host. J Exp Med 2004, 200:1083-1089.
44. Wagner U., Pierer M., Wahle M., Moritz F., Kaltenhauser S., Hantzschel H. Ex vivo homeostatic proliferation of CD4+ T cells in rheumatoid arthritis is dysregulated and driven by membrane-anchored TNFalpha. J Immunol 2004, 173:2825-2833.
45. Lawson B.R., Koundouris S.I., Barnhouse M., Dummer W., Baccala R., Kono D.H., et al. The role of alpha beta+ T cells and homeostatic T cell proliferation in Y-chromosome-associated murine lupus. J Immunol 2001, 167:2354-2360.
46. MacMurray A.J., Kwitek A.E., Rutledge E.A., Van Yserloo B., Gohlke P., Speros S.J., et al. Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene. Genome Res 2002, 12:1029-1039.
47. Hornum L., Romer J., Markholst H. The diabetes-prone BB rat carries a frameshift mutation in Ian4, a positional candidate of Iddm1. Diabetes 2002, 51:1972-1979.
48. Landthaler M., Yalcin A., Tuschl T. The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol 2004, 14:2162-2167.
49. Rolston K.V. Management of infections in the neutropenic patient. Annu Rev Med 2004, 55:519-526.
50. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
51. Elde N.C., Malik H.S. The evolutionary conundrum of pathogen mimicry. Nat Rev Microbiol 2009, 7:787-797.
52. Kountouras J., Deretzi G., Grigoriadis N., Zavos C., Boziki M., Gavalas E., et al. Guillain-Barre syndrome. Lancet Neurol 2008, 7:1080-1081. author reply 3-5.
53. Scheinberg P., Young N.S. How I treat acquired aplastic anemia. Blood 2012, 120:1185-1196.
54. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
55. Chen C., Liu Y., Zheng P. Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice. J Clin Invest 2010, 120:4091-4101.
56. Inoki K., Corradetti M.N., Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005, 37:19-24.
57. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4:648-657.
58. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126:955-968.
59. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
60. Gao X., Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 2001, 15:1383-1392.
61. Potter C.J., Huang H., Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001, 105:357-368.
62. Potter C.J., Pedraza L.G., Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002, 4:658-665.
63. Potter C.J., Pedraza L.G., Huang H., Xu T. The tuberous sclerosis complex (TSC) pathway and mechanism of size control. Biochem Soc Trans 2003, 31:584-586.
64. Lee D.F., Kuo H.P., Chen C.T., Hsu J.M., Chou C.K., Wei Y., et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007, 130:440-455.
65. Russell R.C., Fang C., Guan K.L. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development 2011, 138:3343-3356.
66. Yang Q., Guan K.L. Expanding mTOR signaling. Cell Res 2007, 17:666-681.
67. Yang Q., Inoki K., Ikenoue T., Guan K.L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 2006, 20:2820-2832.
68. Huang J., Dibble C.C., Matsuzaki M., Manning B.D. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 2008, 28:4104-4115.
69. Yang Q., Inoki K., Kim E., Guan K.L. TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc Natl Acad Sci U S A 2006, 103:6811-6816.
70. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441:475-482.
71. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006, 441:518-522.
72. Tothova Z., Kollipara R., Huntly B.J., Lee B.H., Castrillon D.H., Cullen D.E., et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007, 128:325-339.
73. Chen C., Liu Y., Liu R., Ikenoue T., Guan K.L., Liu Y., et al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 2008, 205:2397-2408.
74. Gambineri E., Torgerson T.R., Ochs H.D. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003, 15:430-435.
75. Ruemmele F.M., Brousse N., Goulet O. Autoimmune enteropathy: molecular concepts. Curr Opin Gastroenterol 2004, 20:587-591.
76. Wildin R.S., Smyk-Pearson S., Filipovich A.H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002, 39:537-545.
77. Barzaghi F., Passerini L., Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol 2012, 3:211.
78. Bindl L., Torgerson T., Perroni L., Youssef N., Ochs H.D., Goulet O., et al. Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). J Pediatr 2005, 147:256-259.
79. Gambineri E., Perroni L., Passerini L., Bianchi L., Doglioni C., Meschi F., et al. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol 2008, 122. 1105-12.e1.
80. Yong P.L., Russo P., Sullivan K.E. Use of sirolimus in IPEX and IPEX-like children. J Clin Immunol 2008, 28:581-587.
81. Sofroniadou S., Goldsmith D. Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf 2011, 34:97-115.
82. Fishbane S., Cohen D.J., Coyne D.W., Djamali A., Singh A.K., Wish J.B. Posttransplant anemia: the role of sirolimus. Kidney Int 2009, 76:376-382.
83. Long S.A., Rieck M., Sanda S., Bollyky J.B., Samuels P.L., Goland R., et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012, 61:2340-2348.
84. Piemonti L., Maffi P., Monti L., Lampasona V., Perseghin G., Magistretti P., et al. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia 2011, 54:433-439.
85. Krueger D.A., Care M.M., Holland K., Agricola K., Tudor C., Mangeshkar P., et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363:1801-1811.
86. Hong J.C., Kahan B.D. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000, 69:2085-2090.
87. Fernandez D., Bonilla E., Mirza N., Niland B., Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54:2983-2988.
88. Ngalamika O., Zhang Y., Yin H., Zhao M., Gershwin M.E., Lu Q. Epigenetics, autoimmunity and hematologic malignancies: a comprehensive review. J Autoimmun 2012, 39:451-465.
89. Selmi C., Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., et al. Mechanisms of environmental influence on human autoimmunity: a national institute of environmental health sciences expert panel workshop. J Autoimmun 2012, 39:272-284.
90. Selmi C., Lu Q., Humble M.C. Heritability versus the role of the environment in autoimmunity. J Autoimmun 2012, 39:249-252.